Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2025-2031) | Size & Revenue, Growth, Trends, Outlook, Forecast, Industry, Companies, Share, Segmentation, Competitive Landscape, Value, Analysis

Name: Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2025-2031) | Size & Revenue
Creator: 6Wresearch
License: https://www.6wresearch.com/privacy-policy

Market Forecast By GLP-1 Receptor Agonists (Exenatide, Liraglutide (Victoza), Lixisenatide (Lyxumia), Dulaglutide (Trulicity), Semaglutide (Ozempic)), By Insulin Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins) And Competitive Landscape

Product Code: ETC7480854	Publication Date: Sep 2024	Updated Date: Nov 2025	Product Type: Market Research Report
Publisher: 6Wresearch	Author: Vasudha	No. of Pages: 75	No. of Figures: 35	No. of Tables: 20

Hong Kong Insulin Drugs and Glucagon-like Peptide 1 (Glp-1) Receptor Agonist Market Top 5 Importing Countries and Market Competition (HHI) Analysis

The import shipments of insulin drugs and GLP-1 receptor agonists to Hong Kong in 2024 continued to show strong growth, with a CAGR of 11.27% from 2020 to 2024. The top exporting countries to Hong Kong include Ireland, Belgium, China, Germany, and Singapore. Despite the growth, market concentration, as measured by the HHI, remained low in 2024. The modest growth rate of 1.49% from 2023 to 2024 indicates steady expansion in the market for these critical pharmaceutical products in Hong Kong.

Hong Kong Insulin Drugs and Glucagon-like Peptide 1 (Glp-1) Receptor Agonist Market Top 5 Importing Countries and Market Competition (HHI) Analysis

Key Highlights of the Report:

Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Outlook
Market Size of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, 2024
Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Revenues & Volume for the Period 2021- 2031
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Trend Evolution
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Drivers and Challenges
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Price Trends
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Porter's Five Forces
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Industry Life Cycle
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By GLP-1 Receptor Agonists for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Exenatide for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Liraglutide (Victoza) for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Lixisenatide (Lyxumia) for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Dulaglutide (Trulicity) for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Semaglutide (Ozempic) for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Insulin Drugs for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Basal or Long-acting Insulins for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Bolus or Fast-acting Insulins for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Traditional Human Insulins for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Combination Insulins for the Period 2021- 2031
Historical Data and Forecast of Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Biosimilar Insulins for the Period 2021- 2031
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Import Export Trade Statistics
Market Opportunity Assessment By GLP-1 Receptor Agonists
Market Opportunity Assessment By Insulin Drugs
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Top Companies Market Share
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Competitive Benchmarking By Technical and Operational Parameters
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Company Profiles
Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Key Strategic Recommendations

Frequently Asked Questions About the Market Study (FAQs):

How does 6Wresearch market report help businesses in making strategic decisions?

Do you also provide customisation in the market study?

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Overview

3.1 Hong Kong Country Macro Economic Indicators

3.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, 2021 & 2031F

3.3 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Industry Life Cycle

3.4 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Porter's Five Forces

3.5 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume Share, By GLP-1 Receptor Agonists, 2021 & 2031F

3.6 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume Share, By Insulin Drugs, 2021 & 2031F

4 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of diabetes in Hong Kong

4.2.2 Growing awareness about the importance of managing diabetes

4.2.3 Technological advancements in insulin drugs and GLP-1 receptor agonists

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for drug approval

4.3.2 High cost associated with insulin drugs and GLP-1 receptor agonists

4.3.3 Limited access to healthcare services for some segments of the population

5 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Trends

6 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By Types

6.1 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By GLP-1 Receptor Agonists

6.1.1 Overview and Analysis

6.1.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By GLP-1 Receptor Agonists, 2021- 2031F

6.1.3 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Exenatide, 2021- 2031F

6.1.4 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Liraglutide (Victoza), 2021- 2031F

6.1.5 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Lixisenatide (Lyxumia), 2021- 2031F

6.1.6 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Dulaglutide (Trulicity), 2021- 2031F

6.1.7 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Semaglutide (Ozempic), 2021- 2031F

6.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By Insulin Drugs

6.2.1 Overview and Analysis

6.2.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Basal or Long-acting Insulins, 2021- 2031F

6.2.3 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Bolus or Fast-acting Insulins, 2021- 2031F

6.2.4 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Traditional Human Insulins, 2021- 2031F

6.2.5 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Combination Insulins, 2021- 2031F

6.2.6 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Biosimilar Insulins, 2021- 2031F

7 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Import-Export Trade Statistics

7.1 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Export to Major Countries

7.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Imports from Major Countries

8 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Key Performance Indicators

8.1 Patient adherence rate to prescribed insulin and GLP-1 receptor agonist treatments

8.2 Number of clinical trials conducted for developing new insulin drugs and GLP-1 receptor agonists

8.3 Adoption rate of digital health solutions for diabetes management

8.4 Number of healthcare professionals trained in diabetes care

8.5 Rate of hospital readmissions for diabetes-related complications

9 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Opportunity Assessment

9.1 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Opportunity Assessment, By GLP-1 Receptor Agonists, 2021 & 2031F

9.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Opportunity Assessment, By Insulin Drugs, 2021 & 2031F

10 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Competitive Landscape

10.1 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenue Share, By Companies, 2024

10.2 Hong Kong Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Global Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Seychelles Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Sierra Leone Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Slovenia Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Solomon Islands Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Somalia Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market